Direct oral anticoagulants (DOACs)

被引：8
|
作者：
Vazquez, Sara [1 ]
Rondina, Matthew T. [2 ,3 ,4 ]
机构：
[1] Univ Utah, Hlth Sci Ctr, Univ Healthcare Thrombosis Serv, Salt Lake City, UT USA
[2] Univ Utah, Dept Internal Med, Div Gen Internal Med, Salt Lake City, UT 84112 USA
[3] Univ Utah, Sch Med, Program Mol Med, Salt Lake City, UT USA
[4] George E Wahlen Salt Lake City VAMC, Dept Internal Med, Salt Lake City, UT USA
来源：
VASCULAR MEDICINE | 2015年 / 20卷 / 06期
关键词：
anticoagulants; apixaban; dabigatran; edoxaban; rivaroxaban; thrombosis; DVT; pulmonary embolism; PATIENT;
D O I：
10.1177/1358863X15600256
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
DOACs are a new group of blood-thinner medications that may have some advantages over warfarin. A health care provider will look at several different factors to help patients decide if a DOAC is a good choice. Patients taking DOACs should discuss medication changes, a plan for taking the DOAC before and after a surgery, and any bleeding side effects with their health care provider.
引用
下载
收藏
页码：575 / 577
页数：3
相关论文
共 50 条
  • [11] Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review
    Sunkara, Tagore
    Ofori, Emmanuel
    Zarubin, Vadim
    Caughey, Megan E.
    Gaduputi, Vinaya
    Reddy, Madhavi
    HEALTH SERVICES INSIGHTS, 2016, 9 : 25 - 36
  • [12] Laboratory monitoring of direct oral anticoagulants (DOACs)-The perfect storm?
    Lippi, Giuseppe
    Favaloro, Emmanuel J.
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (01)
  • [13] Direct oral anticoagulants (DOACs): From the laboratory point of view
    Margetic, Sandra
    Goreta, Sandra Supraha
    Celap, Ivana
    Razum, Marija
    ACTA PHARMACEUTICA, 2022, 72 (04) : 459 - 482
  • [14] EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN MORBIDLY OBESE PATIENTS
    Kalani, Charlene
    Henry, Elizabeth Awudi
    Alexander, Thomas
    Udeani, George
    Surani, Salim
    CHEST, 2018, 154 (04) : 108A - 108A
  • [15] Laboratory coagulation tests in patients treated by direct oral anticoagulants (DOACs)
    Sie, Pierre
    PRESSE MEDICALE, 2015, 44 (7-8): : 772 - 778
  • [16] Risk of Hemorrhoidal Bleeding in Patients Treated with Direct Oral Anticoagulants (DOACs)
    Petruzziello, Carmine
    Saviano, Angela
    Brigida, Mattia
    Migneco, Alessio
    Manetti, Luca Luigi
    Candelli, Marcello
    Ojetti, Veronica
    GASTROINTESTINAL DISORDERS, 2024, 6 (03): : 634 - 643
  • [17] Bleeding and the direct oral anticoagulants (DOACS) in the <55 year group
    Myers, B.
    Willcocks, M.
    THROMBOSIS RESEARCH, 2017, 151 : S132 - S132
  • [18] Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
    Burnett, Allison E.
    Mahan, Charles E.
    Vazquez, Sara R.
    Oertel, Lynn B.
    Garcia, David A.
    Ansell, Jack
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2016, 41 (01) : 206 - 232
  • [19] Safety of direct oral anticoagulants (DOACs) in patients with advanced liver disease
    Semmler, Georg
    Pomej, Katharina
    Bauer, David J. M.
    Balcar, Lorenz
    Simbrunner, Benedikt
    Binter, Teresa
    Hartl, Lukas
    Becker, Jeanette
    Pinter, Matthias
    Quehenberger, Peter
    Trauner, Michael
    Mandorfer, Mattias
    Lisman, Ton
    Reiberger, Thomas
    Scheiner, Bernhard
    JOURNAL OF HEPATOLOGY, 2021, 75 : S374 - S375
  • [20] Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs)
    Megan C. Herink
    Yan F. Zhuo
    Craig D. Williams
    Thomas G. DeLoughery
    Drugs, 2019, 79 : 1625 - 1634
12345